Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in...
Alti Rahman and Susan Sabo-Wagner were selected as panelists at the Association of Cancer Care Centers event in Washington, D.C....
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses...
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of...
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first...
Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean...
OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more...
STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in...
Dermalyser AI-driven support tool achieved remarkable sensitivity and specificity values of 95% and 85%, respectively, with these figures increasing to...
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,...
Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk...
LEXINGTON, KY / ACCESSWIRE / March 5, 2024 / NX Development Corp. (NXDC) has achieved another milestone as we proudly...
LUND, SE / ACCESSWIRE / March 5, 2024 / Cantargia (STO:CANTA) (Cantargia AB);(Nasdaq Stockholm: CANTA) today reported new preclinical data...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--LinusBio, a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list...
Results From a Large-Scale Prospective Study Investigating Long-Term Anti-Estrogen Therapy Recommendations Published in JNCCN — Journal of the National Comprehensive...
Sixty Percent of Surveyed Members Identified They Are Managing an Ongoing Health ConditionCHICAGO, IL / ACCESSWIRE / March 5, 2024...
NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / Gilead SciencesOriginally published by SAN FRANCISCO BUSINESS TIMES on bizjournals.comMuch has...
Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected...